INmune Bio Inc. and Quantum Computing Inc. Partner to Apply Quantum Optimization and AI to Advance Alzheimer’s Drug Research and Explore New Applications for XPro ™

INmune Bio and Quantum Computing Inc. announced a collaboration applying QCi's Dirac-3S quantum optimization machine with AI to INMB's clinical and biomedical datasets to find new indications and biomarkers for XPro. The Stage 1 engagement is QCi's first commercial customer in pharma/biotech; no financial terms were disclosed. INMB plans to prioritize indications starting with rare diseases where trials are smaller and capital-efficient, and where pediatric approvals may earn a Priority Review Voucher.

AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.